comparemela.com

Latest Breaking News On - பூக்கும் பர்டன் பத்திரங்கள் - Page 1 : comparemela.com

Satellos Bioscience Inc : Satellos and iCo Therapeutics Announce Completion of Reverse Takeover

Toronto, Ontario (Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following

Microbix Announces $6 0 Million of Financings

Microbix Announces $6 0 Million of Financings
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

iCo Therapeutics Inc Announces Closing of Upsized Subscription Receipt Private Placement

iCo Therapeutics Inc Announces Closing of Upsized Subscription Receipt Private Placement
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

iCo Therapeutics Inc Announces Upsized Subscription Receipt Private Placement

iCo Therapeutics Inc Announces Upsized Subscription Receipt Private Placement
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Field Trip Health Ltd Announces Closing of $95 Million Bought Deal Financing

Message : Required fields . TORONTO, March 17, 2021 (GLOBE NEWSWIRE) Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ( Field Trip ), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021, including the full exercise of the underwriters’ over-allotment option (the Offering ). In connection with the Offering, Field Trip issued 14,661,499 common shares, (“ Common Shares”) at a price of C$6.50 per Common Share, for aggregate gross proceeds of $95 million. The lead investor in the Offering was Soleus Capital with additional participation by Avidity Partners, Sphera Funds, Pura Vida Investments, Jennison Associates and other healthcare specialized institutional investors.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.